KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Common Equity: 2009-2024

Historic Common Equity for Idexx Laboratories (IDXX) over the last 16 years, with Dec 2024 value amounting to $1.6 billion.

  • Idexx Laboratories' Common Equity fell 3.51% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year decrease of 3.51%. This contributed to the annual value of $1.6 billion for FY2024, which is 7.46% up from last year.
  • As of FY2024, Idexx Laboratories' Common Equity stood at $1.6 billion, which was up 7.46% from $1.5 billion recorded in FY2023.
  • In the past 5 years, Idexx Laboratories' Common Equity registered a high of $1.6 billion during FY2024, and its lowest value of $608.7 million during FY2022.
  • Over the past 3 years, Idexx Laboratories' median Common Equity value was $1.5 billion (recorded in 2023), while the average stood at $1.2 billion.
  • As far as peak fluctuations go, Idexx Laboratories' Common Equity surged by 255.85% in 2020, and later decreased by 11.78% in 2022.
  • Yearly analysis of 5 years shows Idexx Laboratories' Common Equity stood at $632.8 million in 2020, then grew by 9.04% to $690.0 million in 2021, then declined by 11.78% to $608.7 million in 2022, then surged by 143.87% to $1.5 billion in 2023, then grew by 7.46% to $1.6 billion in 2024.